Celltrion (068270) Investor presentation summary

Business priorities

• Target 22 biosimilar products by 2030, spanning differentiated formulations, dosages and administration routes.

• Aim to enter clinical studies for at least 10 novel drug candidates across multiple modalities by 2027.

• Expand direct sales across Europe and the US to support flexible pricing, bundling and broader market reach.

Biosimilar portfolio and commercial update

• Remsima IV and SC reached 75% combined market share in EU5; market share was based on prescription volume.

• Yuflyma 1H24 sales of KRW 147bn exceeded FY2023 sales of KRW 143bn; Vegzelma 1H24 sales reached KRW 74.6bn versus KRW 49.4bn in FY2023.

• 2Q24 sales of Remsima IV, Remsima SC, Yuflyma and Vegzelma each reached quarterly records; new biosimilars rose to 30.2% of biopharmaceutical sales from 26.5% in 2Q23.

Novel drug development

• Zymfentra, the first and only subcutaneous infliximab, secured 75% of US insurance-market coverage within five months of launch.

• Formulation patent protection extends to 2037 and administration-method patent protection to 2038–2040; contracts were secured with all three major PBMs, including ESI.

• Infliximab was described as strongly recommended across major US guidelines for UC and CD; surveyed gastroenterologists preferred it for 28% of UC and 34% of CD responses.